Growth Metrics

Tvardi Therapeutics (TVRD) Cash from Financing Activities (2016 - 2025)

Tvardi Therapeutics' Cash from Financing Activities history spans 13 years, with the latest figure at $1000.0 for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 100.0% to $1000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $22.7 million, a 15.91% decrease, with the full-year FY2025 number at $22.7 million, down 15.91% from a year prior.
  • Cash from Financing Activities hit $1000.0 in Q4 2025 for Tvardi Therapeutics, up from -$322000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for TVRD hit a ceiling of $45.3 million in Q4 2021 and a floor of -$685000.0 in Q1 2024.
  • Historically, Cash from Financing Activities has averaged $7.1 million across 5 years, with a median of $339000.0 in 2021.
  • Biggest five-year swings in Cash from Financing Activities: surged 165695.45% in 2023 and later crashed 2200.0% in 2025.
  • Tracing TVRD's Cash from Financing Activities over 5 years: stood at $45.3 million in 2021, then plummeted by 99.95% to $22000.0 in 2022, then surged by 165695.45% to $36.5 million in 2023, then decreased by 25.95% to $27.0 million in 2024, then tumbled by 100.0% to $1000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for TVRD at $1000.0 in Q4 2025, -$322000.0 in Q3 2025, and $22.0 million in Q2 2025.